Clinical-stage biopharmaceutical company Peregrine Pharmaceuticals Inc (PPHM) Wednesday highlighted positive data from two Phase I investigator-sponsored trials and one preclinical study while evaluating the potential of bavituximab when combined with standard approved therapies in breast, liver and prostate cancers.
The company stated that in a Phase I trial of bavituximab with paclitaxel in five evaluable patients with HER-2 negative metastatic breast cancer, two patients achieved a complete tumor response, one achieved a partial response, and two had progressive disease according to Response Evaluation Criteria In Solid Tumors measurement criteria.
Additionally, the company presented data from a Phase I/II trial investigating bavituximab with sorafenib in patients with advanced hepatocellular carcinoma, in which no dose-limiting toxicities or serious adverse events were observed in the first phase of the trial.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org